MENLO PARK, Calif. and NEW YORK, March 11, 2020 /PRNewswire/ -- New Enterprise Associates, Inc. (NEA) today announced that it has closed on $3.6 billion for its latest fund, bringing the firm's committed capital to nearly $24 billion over its 42-year history. In conjunction with the new fund, Liza Landsman has been named General Partner. Landsman, who joined the firm's New York office as a Venture Partner in 2018 after serving as president of NEA portfolio company, focuses on software and services investments across the consumer landscape.


FDA Logo

U.S. prescription drugs can broadly be divided into two categories: 1) small molecule drugs and 2) biologics. Small molecule drugs tend to be chemically synthesized and often have molecular weights under 1,000 Daltons. Contrastingly, biologic drugs are larger and more complex molecules, for example proteins, viruses, and living cells such as CAR-T cells.


Scientist Drugstore Microscope Free photo on Pixabay

OSLO, NORWAY, March 10, 2020 – CEPI, the Coalition for Epidemic Preparedness Innovations, today announced the expansion of its COVID-19 vaccine portfolio. CEPI will be investing a further $4.4 million in partnering agreements with Novavax, Inc. and The University of Oxford to rapidly develop vaccine candidates against COVID-19. This brings CEPI’s total investment in COVID-19 vaccine R&D to $23.7 million.


Welldoc Announces Collaboration with Dexcom to Enhance the Value of BlueStar® with the Dexcom G6® CGM System Welldoc Inc

Columbia, MD – March 11, 2020 – Welldoc, a leading digital health company, announced today a collaboration with Dexcom, the global leader in continuous glucose monitoring (CGM) systems for people with diabetes. Welldoc and Dexcom signed an initial data partnership in 2019. This new collaboration will allow Welldoc’s award-winning BlueStar®, a digital health product for individuals living with type 1 and type 2 diabetes, to deliver insights to Dexcom G6® CGM system users. These insights go beyond glucose trends to inform individuals how their glucose is being affected by other key parameters, including medication adherence, activity, nutrition, sleep and more. The parties will also explore additional opportunities with Welldoc customers to leverage a more integrated offering.



BALTIMORE — Two Johns Hopkins microbiologists have developed an in-house coronavirus screening test that may soon allow the health system to test as many as 1,000 people per day.

Karen Carroll, M.D., and Heba Mostafa, M.B.B.Ch., Ph.D are the microbiologists leading this.

“We will be able to diagnose more cases. This will allow the control of exposure,” said Mostafa, assistant professor of pathology and director of the molecular virology laboratory at The Johns Hopkins Hospital.

Image: Photo by: Johns Hopkins Medicine

Mark Suzman

The Bill & Melinda Gates Foundation is teaming up with Wellcome and Mastercard to form the COVID-19 Therapeutics Accelerator, a $125 million effort to help find potential treatments for the coronavirus epidemic and future threats.

The accelerator will bring together the World Health Organization, pharmaceutical companies, biotech firms, government, and other philanthropic groups to develop therapies for COVID-19.

Image: Mark Suzman. (Gates Foundation Photo)

Stop Road Sign Warning Free vector graphic on Pixabay

The number of cases of SARS-CoV-2 coronavirus infection, and COVID-19, the disease caused by the virus, continue to increase in the United States—both in number and in location (real-time map). At the same time, the number and severity of symptoms post-infection can vary by age and other risk factors (CDC Report). High level officials and politicians have been reported to be infected by, or in contact with, the virus. And there is no U.S. Food and Drug Administration (FDA) approved or licensed cure for COVID-19 (other than time, supportive measures as necessary, and a healthy immune system). "Although there are investigational COVID-19 vaccines and treatments under development, these investigational products are in the early stages of product development and have not yet been fully tested for safety or effectiveness."


Pills Medicine Medical Free image on Pixabay

GEN publishes its updated annual A-List highlighting the top 15 best-selling drugs of 2019. Eleven of last year’s 15 top-selling drugs registered year-over-year sales gains, with seven of the 11 racking up double-digit increases . . .



All TBS Osteo features and main arguments. Included, in greater detail.

  • What is TBS Osteo powered by TBS iNsight and what is TBS (Trabecular Bone Score): the main arguments. 
  • TBS Osteo compatibilities with different DXA systems. 
  • Main evidence of TBS clinical validation. 
  • How TBS can be a significant aid to better characterize your patient’s risk profile. 
  • Short grid to understand the risk of fracture based on a combined model of TBS and BMD. 

Updated for TBS Osteo 3.1



Last Wednesday, the House Science Committee, Subcommittee on Research and Technology, invited Under Secretary of Commerce and Director of the National Institute of Standards and Technology (NIST) Dr. Walter Copan to testify before the Subcommittee on reauthorizing the agency. NIST was last authorized in 2016 as part of the American Innovation and Competitiveness Act. Director Copan’s testimony covered each of the technologies the Trump Administration is collectively referring to as “industries of the future,” including Quantum Information Science, Artificial Intelligence, 5G, Advanced Manufacturing, and Biotechnology. He specifically commented on how NIST catalyzes partnerships between industry, academia, government, and other organizations to promote U.S. innovation and economic competitiveness.



Precise loading of diverse peptides for vaccination is enabled by a strategy for peptide–TLR7/8 conjugate self-assembly of uniform nanoparticles. The approach is compatible with the development of personalized strategies, such as cancer vaccines targeting patient-specific neoepitopes.


University of Maryland Logo

University of Maryland athletics on Wednesday announced a series of safety measures for its home events amid concern over the coronavirus outbreak, now labeled a pandemic by the World Health Organization.

Among several changes announced in a release, "Effective immediately, only student-athletes, coaches, essential personnel, officials, credentialed media and a limited number of family members of the competing teams will be permitted to attend games, until at least April 10.”


NEA New Enterprise Associates

New Enterprise Associates has raised $3.6 billion for its 17th venture fund, the largest in the more than 42-year history of the firm.

NEA set out in the second quarter of 2019 to raise New Enterprise Associates 17 LP and held a final closing in February at its target, said General Partner Mohamad Makhzoumi.


Biotalk Skyscraper Rich And Chris Frew

BioBuzz and Workforce Genetics Founder, Chris Frew, Joins BioTalk to discuss building two organizations, talent acquisition, and his role in the BioHealth Capital Region ←Sub title

Chris is the Founder and CEO of Workforce Genetics, LLC (WGx), and BioBuzz Media to foster highly engaging experiences that connect people and companies across biohealth ecosystems. His insights into talent attraction, employer branding, and marketing have helped top companies to tackle their most pressing challenges in the new talent economy. Previously as Vice President at Breezio, a leading innovator in cloud-based online communities, he lead the development of the new Internship Network of Maryland (inMD) platform that was approved by Gov. Hogan in 2017. As Vice President of Tech USA’s Scientific Division Chris founded and ran a national staffing division operating at $23M annually when he left in 2015. Chris is passionate about impacting others, especially his family and his team, and helping to foster a strong community within the BioHealth Capital Region. He is a Maryland native and a graduate of Towson University. Learn more at and


Register Now for the 6th Annual BioHealth Capital Region (BHCR) Forum held on April 14-15 at AstraZeneca in Gaithersburg, MD. Join your peers biotech and life science executives and expert speakers from industry, academia, healthcare, government, finance and real estate development, among others, converged to discuss the BHCR’s path forward to becoming a top three U.S. biotech cluster by 2023.

Register Now

Qiagen Logo

U.S. laboratory equipment maker Thermo Fisher Scientific Inc. agreed to buy Qiagen NV, a Dutch maker of tests for diseases including cancer and the new coronavirus, for about 9 billion euros ($10 billion) in the biggest health-care acquisition so far this year.

Investors will get 39 euros in cash for every Qiagen share, Thermo Fisher said Tuesday. That’s 23% higher than Monday’s closing price. Qiagen also sells products for food and forensic testing. Bloomberg earlier reported the companies were nearing a deal after reviving discussions that broke off late last year.


BHI Logo


BioHealth Innovation, Inc. (BHI), is a Montgomery County innovation intermediary which translates market-relevant research into commercial success by bringing together management, funding, and markets. BHI is seeking a life sciences professional with consulting, market research and/or portfolio management experience to join the BHI's team and serve as a Senior Analyst, Ph.D. to manage and support the Analyst team through training and front facing of potential start-up CEOs and Companies.


The Senior Analyst will manage the analysts and provide project support and guidance to the team as well as to new entrepreneurs on projects including SBIR Grants, corporate and private investments. This will entail market, technology, regulatory and other business intelligence research to support BHI consulting, coaching of companies and the Analyst team profit center. This is a hands-on leadership position. 

Download the Full Job Description.

Coronavirus vaccine news boosting Gaithersburg s Novavax Washington Business Journal

Novavax Inc. is already cashing in on its stock spike after announcing plans to develop a vaccine for the COVID-19 coronavirus.

The Gaithersburg biotech has raked in $98.7 million in net proceeds this quarter from selling 10.5 million shares of common stock at $9.55 per share, the company reported Monday in Securities and Exchange Commission filings. And it could sell up to $150 million more in common stock shares, the company said.

Novavax’s (NASDAQ: NVAX) stock was trading at $12.09 per share Monday early afternoon — which, though down about 24% from Friday’s close (as stocks see general volatility amid the coronavirus outbreak), is still notably high for the Maryland biotech.

Image: Novavax is developing a vaccine candidate for the COVID-19 coronavirus. This Centers for Disease Control and Prevention illustration shows the structure of coronaviruses. CENTERS FOR DISEASE CONTROL AND PREVENTION

Cel Sci Cel Sci Corp

CEL-SCI Corporation (NYSE:CVM) announces that it is developing an immunotherapy with the potential to treat the COVID-19 coronavirus using its patented LEAPS peptide technology. The LEAPS peptides will utilize conserved regions of coronavirus proteins to stimulate protective cell mediated T cell responses and reduce viral load. The LEAPS peptide technology can be used to construct immunotherapeutic peptides that exhibit both antiviral and anti-inflammatory properties. Consequently, these products not only target the virus infection against which they are directed, but also elicit the appropriate protective response(s) against it.


Montgomery College

Montgomery College and George Mason University (Mason), in collaboration with AWS Educate, will partner to create a Bachelor of Applied Science (BAS) pathway in cloud computing. This degree offers students a seamless transfer pathway from a two-year associate’s degree to a four-year bachelor’s degree in cloud technology, providing a clear path to high-demand careers in cloud computing with AWS (Amazon Web Services) partners and customers.



Are you an experienced biohealth industry executive seeking full time or part time employment as a consultant or start-up C suite executive? BioHealth Innovation is updating its database of experienced industry executives who may be able to share their expertise with early stage/growing companies. To be considered by companies or technology transfer organizations seeking leaders for their spin-out companies and/or advisors to support their business growth, please this form and upload a copy of your resume. (For questions/more information, please email: This email address is being protected from spambots. You need JavaScript enabled to view it..)


Tomorrow and every day, we recognize the hashtag#RareDisease community on behalf of the Innate Pharma team. We do what we do because of you. hashtag#RareDiseaseDay hashtag#WRDD hashtag#HairyCellLeukemia hashtag#cutaneouslymphoma hashtag#SézarySyndrome hashtag#MycosisFungoides



Immunomic Therapeutics, Inc., a privately held clinical stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms, announced today that it successfully completed a pre-IND (Investigational New Drug) meeting with the U.S. Food and Drug Administration (FDA) regarding its First-In-Human (FIH) Phase I trial and development plans for ITI-1001. The FDA addressed the Company’s questions and provided feedback on key components of the planned IND application for the candidate, ITI-1001, for the treatment of newly diagnosed Glioblastoma Multiforme (GBM).


company logo1


Novel Mechanism of Action Inhibits Pathological Activation of Microglial Cells and Prevents Neuronal Cell Death

Neuraly, a clinical stage biotechnology company pioneering disease-modifying agents for neurodegenerative disorders, today announced the dosing of the first patient in its Phase 2 clinical trial of NLY01 for Parkinson’s disease.

“Current therapies for Parkinson’s disease provide only temporary symptomatic improvement and fail to slow or halt the relentless progression of the disease,” said Seulki Lee, Ph.D., President and Chief Executive Officer of Neuraly. “The initiation of this Phase 2 study is an important milestone in the ongoing advancement of NLY01 which we believe has the potential to be a ground-breaking therapy for Parkinson’s patients based on results we have seen to date in preclinical trials.”


Black Farmed Eyeglasses in Front of Laptop Computer Free Stock Photo

A Cyber Living Innovation Lab with robotic platforms to evaluate 5G performance and a fleet of driverless cars will provide experiential learning opportunities to students from universities across the region as the anchor of George Mason University’s cybersecurity research expansion, thanks to $2.5 million in funding as part of a statewide initiative.



As part of the government-wide effort to mitigate the spread of COVID-19 in U.S. communities, the U.S. Department of Health and Human Services (HHS) has updated a broad agency announcement (BAA) to focus specifically on products to diagnose, prevent or treat coronavirus infections.

The Biomedical Advanced Research and Development Authority (BARDA), part of the HHS Office of the Assistant Secretary for Preparedness and Response (ASPR), issued the BAA, BAA-18-100-SOL-00003-Amendment 13, to solicit proposals for advanced development and licensure of COVID-19 diagnostics, vaccines, or medicines such as therapeutics or antivirals.

“Amid the expanding global outbreak of COVID-19, Americans need diagnostics, vaccines, and medicines to mitigate the potential impact of this virus”, said BARDA Director Rick Bright, Ph.D. “To accelerate the availability of these lifesaving tools, BARDA took an important step today to request proposals for development of COVID-19 diagnostics, vaccines, or therapeutics, many of which will be developed using existing platform technologies to permit rapid development.”


Joel S. Marcus

PASADENA, Calif. and NEW YORK, March 6, 2020 /PRNewswire/ -- Alexandria Real Estate Equities, Inc. (NYSE: ARE), an urban office REIT and the first, longest-tenured and pioneering owner, operator and developer uniquely focused on collaborative life science, technology and agtech campuses in AAA innovation cluster locations, and its executive chairman and founder, Joel S. Marcus, were honored to receive the 2020 Navy SEAL Foundation Patriot Award. This recognition highlights Alexandria's contributions to our nation and unwavering support for the Naval Special Warfare community, as well as its embodiment of the values that epitomize the SEAL community. Congressional Medal of Honor recipient and retired U.S. Navy Master Chief Special Warfare Operator Britt Slabinski presented the prestigious award to Mr. Marcus yesterday evening during the Navy SEAL Foundation's 12th annual New York City Benefit Dinner celebrating the Foundation's 20th anniversary.



If you’ve been on the web to learn more about the latest pandemic, chances are you’ve stumbled upon at least one or two coronavirus dashboards. These are the landing pages for interactive maps and visuals that show where the virus has spread, as well as numbers on the latest in infection rates and deaths, breakdowns of what countries are suffering from new cases and what regions are likely seeing new outbreaks, and much more.


Home Maryland Economic Development Association MEDA

The Maryland Economic Development Association (MEDA) is proud to announce the winners of the 2020 MEDA Awards. The 2020 awards, sponsored by Miles & Stockbridge P.C., recognize the exceptional people, programs and projects that bring economic prosperity to Maryland.

“We’d like to thank all who submitted a nomination for recognizing such deserving programs, projects and individuals, and our awards judges for their hard work determining the winners,” says Pamela Ruff, MEDA executive director. “The 2020 winners exemplify the Maryland communities that are going above and beyond when it comes to economic expansion and prosperity.”



The region’s politicians and business leaders are mourning the fact Baltimore stands to lose another headquarters of a prestigious, publicly traded company with the news that Legg Mason Inc. was acquired by Franklin Resources Inc. But investors should remain bullish about the city’s business future. The acquisition of Legg Mason was part of a natural cycle of industry consolidation and not a measure of Baltimore’s business climate. In fact, Baltimore and the surrounding region are poised to lead a business revolution in health.



As the world scrambles to monitor and contain the COVID-19 outbreak, drug companies are racing to develop or repurpose treatments to combat the potential pandemic. The death toll continues to climb. The first U.S. death associated with the SARS-CoV-2 virus was reported in Washington state February 29. As of March 2, according to the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University, 3,048 people in 11 countries had died worldwide, nearly all of them (96% or 2,914) in China.

Image: Credit: NASA/Johns Hopkins University Applied Physics Laboratory/Southwest Research Institute/Roman Tkachenko


What is Crab Pot?

The Crab Pot Pitch Competition is Southern Maryland’s premier pitch competition for entrepreneurs with cutting edge, disruptive and innovative technologies. Made popular by television shows like ABC’s “Shark Tank,” pitch contests provide an opportunity for entrepreneurs to present their ideas to a panel of judges or investors in front of an audience.

Crab Pot provides an opportunity for the community to celebrate the efforts of local entrepreneurs and innovators. Audience members get to see what entrepreneurs in Southern Maryland are up to. Crab Pot provides an opportunity for the community to celebrate the efforts of local entrepreneurs and innovators. Audience members get to see what entrepreneurs in Southern Maryland are up to. Entrepreneurs get to practice their pitches and win cash prizes. This year will be the 6th annual competition!


Renaissance Capital Logo

Facing record-high volatility and market uncertainty, one biotech is scheduled for the week ahead.

Formed by New Enterprise Associate's orphan drug accelerator Cydan, genetic disorder biotech Imara (IMRA) plans to raise $76 million at a $301 million market cap. The Boston-based company's sole candidate IMR-687 is a once-a-day therapy targeting sickle cell disease and beta-thalassemia by inhibiting PDE9. It is expected to begin a Phase 2b trial in the 1H20. While there is significant unmet medical need for both disorders, it is a crowded space, with three products approved in 2019.


Allergy Cold Disease Free photo on Pixabay

With more than 378 confirmed coronavirus cases in the U.S. and more than 15 associated deaths, the Centers for Disease Control and Prevention (CDC) is actively monitoring, and trying to contain, the transmission of the disease, called COVID-19. 

In some cases, depending on risk level, the CDC may ask individuals or families to self-quarantine or remain in isolation. Here's a look at what that means and tips for implementing such measures.